Healthy Directions After Lung Surgery Pilot

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02135211
Collaborator
Brigham and Women's Hospital (Other), University of Massachusetts, Boston (Other)
42
2
1
33
21
0.6

Study Details

Study Description

Brief Summary

The objective of this proposal is to test the feasibility and acceptability of a lifestyle risk reduction intervention for patients with lung cancer receiving surgical treatment. This study will provide the preliminary data needed to conduct a larger randomized controlled trial that tests an innovative, multidisciplinary intervention that has the potential to transform the standard of care for patients receiving surgical treatment for lung cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Lifestyle counseling
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
42 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Feasibility and Acceptability of a Lifestyle Intervention for Patients Receiving Surgical Treatment for Lung Surgery
Actual Study Start Date :
Sep 1, 2012
Actual Primary Completion Date :
Oct 1, 2014
Actual Study Completion Date :
Jun 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lifestyle counseling

This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.

Behavioral: Lifestyle counseling

Outcome Measures

Primary Outcome Measures

  1. Feasibility and acceptability [at end of study (4 months post intervention)]

    The primary outcome measures to establish feasibility and acceptability of the intervention for this study are enrollment rates.

  2. Feasibility and acceptability [at end of study (4 months post intervention)]

    The primary outcome measures to establish feasibility and acceptability patient's use of intervention materials

  3. Feasibility and acceptability [at end of study (4 months post intervention]

    The primary outcome measures to establish feasibility and acceptability of the completion of self-monitoring

  4. Feasibility and acceptability [at end of study (4 months post intervention)]

    The primary outcome measures to establish feasibility and acceptability of the intervention for this study completion of nurse-patient contacts.

Secondary Outcome Measures

  1. Interest for this study [baseline, 1 month, & 4 month]

    The secondary outcome measures of interest for this study are lifestyle risk reduction and Health Related-Quality of Life.

  2. Interest for this study [baseline, 1 month, & 4 month]

    The secondary outcome measures of interest for this study is an interview to evaluate the intervention will be conducted with the participant and the partner at the conclusion of the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Patient Inclusion Criteria:
  • 21 years of age

  • English speaking

  • MD approval to participate in study

  • Meets one of the inclusions below:

    1. a histological diagnosis of NSCLC undergoing potentially curative treatment
    1. OR those undergoing surgical procedures for lung cancer (includes patients undergoing diagnostic testing or those presenting with lung nodules
  • 3.OR patients who have had a surgical procedure for lung cancer within the last six months.

  • May invite a buddy to join study with them defined as a friend, partner, adult child or sibling

Buddy Inclusion Criteria:
  • ≥ 21 years of age,

  • English speaking, who is invited by the subject to join as a support person (e.g., friend, partner, adult child or sibling)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brigham & Woman's Hospital Boston Massachusetts United States 02115
2 Dana Farber Cancer Institute Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • University of Massachusetts, Boston

Investigators

  • Principal Investigator: Mary E. Cooley, PhD, RN, FAAN, Dana Farber Cancer Insitute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mary E. Cooley, Phd, Nurse Scientist, PhD, CRNP, FAAN, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT02135211
Other Study ID Numbers:
  • 12-150
First Posted:
May 9, 2014
Last Update Posted:
Jul 2, 2018
Last Verified:
Jun 1, 2018
Keywords provided by Mary E. Cooley, Phd, Nurse Scientist, PhD, CRNP, FAAN, Dana-Farber Cancer Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 2, 2018